Social Responsibility

Sustainable Development

Public welfare activity

World Osteoporosis Day: Multiple experts recommend a “bone–muscle integrated approach”

World Osteoporosis Day: Multiple experts recommend a “bone–muscle integrated approach”

October 20 is World Osteoporosis Day. On that day, the “2026 Health Bones Public Education Conference,” part of China’s Health Knowledge Dissemination Incentive Program, was held in Beijing. The event was co-organized by the China Health Promotion Foundation, the Osteoporosis and Bone Mineral Salt Diseases Branch of the Chinese Medical Association, and People’s Medical Publishing House. During the conference, the Chinese theme for World Osteoporosis Day 2026—“Joint Management of Bone and Muscle, Together Promoting Health”—was unveiled and explained. Experts in attendance provided in-depth insights into bone and muscle health and called on all sectors of society to seize World Osteoporosis Day as an opportunity to launch targeted public education campaigns, amplifying the message of this awareness day and further enhancing public understanding of osteoporosis and sarcopenia. They urged efforts to promote early screening and prevention, ensure standardized diagnosis and treatment, and work together to safeguard bone and muscle health.

→

View Details

10-21

2026

Hunan Xianshi Pharmaceutical Receives NMPA Marketing Approval for Two Strengths of Dapoxetine Hydrochloride Tablets

Hunan Xianshi Pharmaceutical Receives NMPA Marketing Approval for Two Strengths of Dapoxetine Hydrochloride Tablets

CHANGSHA, Jan 09, 2026 — Hunan Xianshi Pharmaceutical Co., Ltd. has obtained marketing authorization from the National Medical Products Administration (NMPA) for Dapoxetine Hydrochloride Tablets in two specifications: 30 mg and 60 mg.

→

View Details

01-09

2026

Since November 2025, these new regulations have been in effect! (With the latest updates for 2026 included.)

Since November 2025, these new regulations have been in effect! (With the latest updates for 2026 included.)

Since November 2025, a series of new regulations on pharmaceutical oversight have been progressively implemented. Let’s take a look at which ones directly affect you.

→

View Details

01-03

2026

Hunan Xianshi Pharmaceutical Attracts Wide Attention at PHARMCHINA 91st National Pharmaceutical Fair in Nanjing

Hunan Xianshi Pharmaceutical Attracts Wide Attention at PHARMCHINA 91st National Pharmaceutical Fair in Nanjing

NANJING, Nov 26, 2025 — The 91st National Pharmaceutical Fair (PHARMCHINA) was held at Nanjing International Expo Center from November 19 to 21. The exhibition gathered over 2,000 top pharmaceutical enterprises and more than 100,000 industry practitioners, acting as a key platform for displaying industrial trends, showcasing corporate strengths and developing commercial cooperation.

→

View Details

11-26

2025

Xianshi Pharmaceutical’s Mannitol–Sorbitol Injection has initiated Phase III clinical trials, with intracranial hypertension as the indication.

Xianshi Pharmaceutical’s Mannitol–Sorbitol Injection has initiated Phase III clinical trials, with intracranial hypertension as the indication.

According to data from the Clinical Trial Registration and Information Disclosure Platform, a multi-center, randomized, double-blind, positive-controlled Phase III clinical study evaluating the safety and efficacy of mannitol–sorbitol injection for the treatment of intracranial hypertension has been initiated by Hunan Xianshi Pharmaceutical Co., Ltd. The clinical trial registration number is CTR20254523, and the date of the initial public disclosure was November 13, 2025.

→

View Details

11-21

2025

< 1234 >